Oncogene Withdrawal Engages the Immune System to Induce Sustained Cancer Regression

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2014 Aug 5

PMID 25089198

Citations 16

Authors

Stephanie C Casey

Yulin Li

Alice C Fan

Dean W Felsher

Affiliations

Soon will be listed here.

Abstract

The targeted inactivation of a single oncogene can induce dramatic tumor regression, suggesting that cancers are "oncogene addicted." Tumor regression following oncogene inactivation has been thought to be a consequence of restoration of normal physiological programs that induce proliferative arrest, apoptosis, differentiation, and cellular senescence. However, recent observations illustrate that oncogene addiction is highly dependent upon the host immune cells. In particular, CD4(+) helper T cells were shown to be essential to the mechanism by which MYC or BCR-ABL inactivation elicits "oncogene withdrawal." Hence, immune mediators contribute in multiple ways to the pathogenesis, prevention, and treatment of cancer, including mechanisms of tumor initiation, progression, and surveillance, but also oncogene inactivation-mediated tumor regression. Data from both the bench and the bedside illustrates that the inactivation of a driver oncogene can induce activation of the immune system that appears to be essential for sustained tumor regression.

Citing Articles

LINC00460/miR-186-3p/MYC feedback loop facilitates colorectal cancer immune escape by enhancing CD47 and PD-L1 expressions.

Luo Q, Shen F, Zhao S, Dong L, Wei J, Hu H J Exp Clin Cancer Res. 2024; 43(1):225.

PMID: 39135122 PMC: 11321182. DOI: 10.1186/s13046-024-03145-1.

Identification of hub genes and their correlation with infiltration of immune cells in positive neuroblastoma based on WGCNA and LASSO algorithm.

Chen J, Sun M, Chen C, Jiang B, Fang Y Front Immunol. 2022; 13:1016683.

PMID: 36311753 PMC: 9596756. DOI: 10.3389/fimmu.2022.1016683.

Mutation or not, what directly establishes a neoplastic state, namely cellular immortality and autonomy, still remains unknown and should be prioritized in our research.

Zhu S, Wang J, Zellmer L, Xu N, Liu M, Hu Y J Cancer. 2022; 13(9):2810-2843.

PMID: 35912015 PMC: 9330459. DOI: 10.7150/jca.72628.

Gut Microbiota and Immunotherapy.

Xu X, Ying J Front Microbiol. 2022; 13:945887.

PMID: 35847121 PMC: 9283110. DOI: 10.3389/fmicb.2022.945887.

Inhibition of the VEGF signaling pathway attenuates tumor‑associated macrophage activity in liver cancer.

Okikawa S, Morine Y, Saito Y, Yamada S, Tokuda K, Teraoku H Oncol Rep. 2022; 47(4).

PMID: 35169858 PMC: 8867251. DOI: 10.3892/or.2022.8282.

References

Casey S, Bellovin D, Felsher D . Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol. 2013; 25(2):246-58. PMC: 3683588. DOI: 10.1016/j.coi.2013.02.003. View

Anders K, Buschow C, Herrmann A, Milojkovic A, Loddenkemper C, Kammertoens T . Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell. 2011; 20(6):755-67. PMC: 3658305. DOI: 10.1016/j.ccr.2011.10.019. View

Furth P . Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations. Ann N Y Acad Sci. 2012; 1271:1-9. PMC: 3471382. DOI: 10.1111/j.1749-6632.2012.06736.x. View

Lawler P, Lawler J . Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med. 2012; 2(5):a006627. PMC: 3331684. DOI: 10.1101/cshperspect.a006627. View

Devaud C, John L, Westwood J, Darcy P, Kershaw M . Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2013; 2(8):e25961. PMC: 3782527. DOI: 10.4161/onci.25961. View

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

Chen J, Schmitt A, Giannopoulos K, Chen B, Rojewski M, Dohner H . Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol. 2007; 31(5):1133-9. View

Krusch M, Salih H . Effects of BCR-ABL inhibitors on anti-tumor immunity. Curr Med Chem. 2011; 18(34):5174-84. DOI: 10.2174/092986711798184271. View

Somasundaram R, Villanueva J, Herlyn M . Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol. 2012; 65:335-59. PMC: 3677516. DOI: 10.1016/B978-0-12-397927-8.00011-7. View

10.

Boxer R, Jang J, Sintasath L, Chodosh L . Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004; 6(6):577-86. DOI: 10.1016/j.ccr.2004.10.013. View

11.

Zhang H, Melamed J, Wei P, Cox K, Frankel W, Bahnson R . Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun. 2003; 3:2. View

12.

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

13.

Peggs K, Quezada S, Allison J . Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008; 224:141-65. DOI: 10.1111/j.1600-065X.2008.00649.x. View

14.

Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12(4):237-51. PMC: 3967236. DOI: 10.1038/nrc3237. View

15.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

16.

Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M . Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002; 297(5578):102-4. DOI: 10.1126/science.1071489. View

17.

Bex A, Etto T, Vyth-Dreese F, Blank C, Griffioen A . Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?. Curr Oncol Rep. 2012; 14(3):230-9. DOI: 10.1007/s11912-012-0229-9. View

18.

Ding Z, Huang L, Blazar B, Yagita H, Mellor A, Munn D . Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood. 2012; 120(11):2229-39. PMC: 3447781. DOI: 10.1182/blood-2011-12-398321. View

19.

Felsher D . Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?. Cancer Res. 2008; 68(9):3081-6. DOI: 10.1158/0008-5472.CAN-07-5832. View

20.

Essmann F, Schulze-Osthoff K . Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol. 2011; 165(2):328-44. PMC: 3268188. DOI: 10.1111/j.1476-5381.2011.01570.x. View